Related Experiment Video
Updated: Jun 23, 2026

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
Published on: March 3, 2023
Progressive reduction using nicotine gum as a prelude to quitting.
Carlos A Jiménez-Ruiz1, Marisa M Ulibarri, Noelia A Besada
1Smokers' Clinic, Institute of Public Health, C/ Santa Cruz del Marcenado, 9 piso 2, Madrid 28015, Spain. victorina@ctv.es
This study shows that gradually reducing cigarettes using nicotine gum is a viable smoking cessation strategy. It helps smokers who prefer not to quit abruptly achieve long-term abstinence.
Area of Science:
- Addiction Medicine
- Public Health
- Behavioral Science
Background:
- Investigated a progressive cigarette reduction program for smokers unwilling to quit abruptly.
- 116 participants (mean age 45.7 years) with a baseline of 28.3 cigarettes/day.
- Utilized nicotine gum as a tool for gradual smoking reduction.
Purpose of the Study:
- To evaluate the feasibility and effectiveness of a two-stage smoking cessation program.
- To assess the impact of progressive reduction using nicotine gum prior to complete cessation.
- To determine abstinence rates at 6-month follow-up.
Main Methods:
- A 4-month reduction phase followed by a 6-month abstinence phase.
- Participants aimed to reduce daily cigarette consumption by 50% by Week 8.
- Nicotine gum (2 or 4 mg) used during reduction; any nicotine replacement therapy (NRT) during abstinence.
- Psychological support and NRT provided free of charge.
Main Results:
- 68% achieved 50% cigarette reduction by Month 2.
- 57% achieved validated abstinence at the target quit date (Week 16).
- 39% maintained continuous abstinence at 6-month follow-up; no nicotine overdose symptoms reported.
Conclusions:
- Progressive cigarette reduction with nicotine gum is a practical approach.
- This strategy is beneficial for smokers hesitant about abrupt cessation.
- Offers a feasible alternative pathway to sustained smoking abstinence.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Drug Dependence
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Phase I Reactions: Reductive Reactions
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
